

Product Information

PADRE

For Research Purposes only. Not for use in Humans



| | |
|---|--|
| Product | BAP-251 |
| Sequence | AKFVAAWTLKAAA H-Ala-Lys-Phe-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-Ala-OH |
| MW / Formula | 1348 / C ₆₅ H ₁₀₂ N ₁₆ O ₁₅ |
| Counter ion | TFA |
| Description | “PADRE” is a peptide that represents a synthetic, universal pan HLA DR-binding epitope, which binds with high or intermediate affinity to most of the common HLA-DR types [1, 2 and literature cited there]. It has been shown, that PADRE supports the generation of CTL responses and are effective for inducing antibody responses. |
| Packaging Reconstitution Storage | The peptide is provided as a lyophilised, colourless powder without any additives. It can be shipped at ambient temperature and should be stored at -20°C. PADRE can be reconstituted in water (1 mg/ml stock solution). Through the use of a vortex mixer, homogeniser or sonicator, a homogenous solution can be prepared. If you use an ultrasonic bath, take care of the vial labels. After reconstitution, the solution should be aliquoted and stored at or below -20°C. Repeated thawing and freezing should be avoided. |
| Handling | Caution, not fully tested. Good laboratory technique should be employed in the safe handling of any peptide product. If you are not fully trained or are unaware of the hazards involved, do not use this compound! Caution: Do not take internally! Avoid contact by all modes of exposure. Wear appropriate laboratory attire including a lab coat, gloves, mask and safety glasses. Do not mouth pipette, inhale, ingest or allow coming into contact with open wounds. Wash thoroughly any area of the body which comes into contact with the product. Avoid accidental autoinoculation by exercising extreme care when handling in conjunction with any injection device. This product is intended for research purposes by qualified personnel only. It is not intended for use in humans or as a diagnostic agent. EMC microcollections GmbH is not liable for any damages resulting from misuse or handling of this product. |
| References | <ol style="list-style-type: none">[1] J. Alexander, J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, R. T. Kubo, A. Sette. H. M. Grey (1994) Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. <i>Immunity</i>. 1994, 751-661.[2] J. Alexander, M. F. del Guercio, A. Maewal, L. Qiao, J. Fikes, R. W. Chesnut, J. Paulson, D. R. Bundle, S. DeFrees, A. Sette (2000) Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. <i>J Immunol</i>. 164, 1625-1633.[3] H. Cong, E.J. Mui, W.H. Witola, J. Sidney, J. Alexander, A. Sette, M. Maewal, K. El Bissati, Y. Zhou, Y. Suzuki, D. Lee, S. Woods, C. Sommerville, F.L. Henriquez, C.W. Roberts, R. McLeod (2012) <i>Toxoplasma gondii</i> HLA-B*0702 restricted GRA720–28 peptide with adjuvants and an universal helper T cell epitope elicits CD8+ T cells producing IFN-γ and reduces parasite burden in HLA-B0702 mice. <i>Hum Immunol</i>. 73, 1–10. doi:10.1016/j.humimm.2011.10.006. |